| Literature DB >> 34601141 |
Hiromu Tanaka1, Ho Lee1, Atsuho Morita1, Ho Namkoong2, Shotaro Chubachi1, Hiroki Kabata1, Hirofumi Kamata1, Makoto Ishii1, Naoki Hasegawa2, Norihiro Harada3, Tetsuya Ueda4, Soichiro Ueda5, Takashi Ishiguro6, Ken Arimura7, Fukuki Saito8, Takashi Yoshiyama9, Yasushi Nakano10, Yoshikazu Mutoh11, Yusuke Suzuki12, Koji Murakami13, Yukinori Okada14, Ryuji Koike15, Yuko Kitagawa16, Katsushi Tokunaga17, Akinori Kimura18, Seiya Imoto19, Satoru Miyano20, Seishi Ogawa21, Takanori Kanai22, Koichi Fukunaga1.
Abstract
BACKGROUND ANDEntities:
Keywords: COVID-19; Clinical character; Host genetics; Japan; Pneumonia
Mesh:
Year: 2021 PMID: 34601141 PMCID: PMC8482546 DOI: 10.1016/j.ijid.2021.09.070
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
Characteristics of 1674 patients with COVID-19 in Japan
| Parameters | Number of patients with data | Subcategories | n (%) or median and IQR |
|---|---|---|---|
| Severity | |||
| classification | 1674 | ||
| Asymptomatic | 51 (3.0) | ||
| Mild | 933 (55.7) | ||
| Severe | 459 (27.4) | ||
| Most severe | 231 (13.8) | ||
| Death at discharge | 1633 | 52 (3.2) | |
| Age, years | 1674 | 59 (45–71) | |
| Sex | 1674 | ||
| Male | 1109 (66.2) | ||
| Female | 565 (33.8) | ||
| Population | 1674 | ||
| Japanese | 1629 (97.3) | ||
| Others | 45 (2.7) | ||
| BMI, kg/m2 | 1525 | 23.9 (21.6–26.9) | |
| Smoking history | 1547 | ||
| Never | 840 (54.3) | ||
| Previously or currently | 707 (45.7) | ||
| Chronic medical conditions | |||
| Hypertension | 1643 | 569 (34.6) | |
| Diabetes mellitus | 1654 | 379 (22.9) | |
| Coronary artery disease | 1657 | 164 (9.9) | |
| Malignancy | 1640 | 97 (5.9) | |
| Autoimmune disease | 1653 | 61 (3.7) | |
| COPD | 1651 | 67 (4.1) | |
| Chronic liver disease | 1592 | 53 (3.3) | |
| Chronic kidney disease | 1579 | 110 (7.0) | |
| Symptoms at referral | |||
| Fever (≥37.5°C) | 1653 | 1311 (79.3) | |
| Cough | 1648 | 959 (58.2) | |
| Sputum | 1642 | 405 (24.7) | |
| Sore throat | 1628 | 387 (23.8) | |
| Rhinorrhea | 1634 | 232 (14.2) | |
| Dysgeusia | 1635 | 305 (18.7) | |
| Dysosmia | 1634 | 278 (17.0) | |
| Shortness of breath | 1616 | 496 (30.7) | |
| Fatigue | 1642 | 811 (49.4) | |
| Laboratory tests | |||
| WBC [cells/μL] | 1613 | 5200 (4100–6700) | |
| LDH [IU/L] | 1634 | 237 (190–314) | |
| Ferritin [ng/mL] | 1269 | 376 (171–711) | |
| KL-6 [U/mL] | 1213 | 234 (178–350) | |
| PCT [ng/mL] | 1165 | 0.06 (0.04–0.11) | |
| CRP [mg/dL] | 1628 | 2.69 (0.51–6.87) | |
| Radiographic imaging | |||
| Chest radiography findings | 1556 | Bilateral thoracic opacities | 834 (53.6) |
| Unilateral thoracic opacities | 180 (11.6) | ||
| 1539 | Bilateral thoracic consolidation | 305 (19.8) | |
| Unilateral thoracic consolidation | 121 (7.9) | ||
| Chest CT findings | 1480 | Bilateral GGO | 1055 (71.3) |
| Unilateral GGO | 148 (10.0) | ||
| 1445 | Bilateral consolidation | 465 (32.2) | |
| Unilateral consolidation | 110 (7.6) | ||
| Complications after referral | |||
| Bacterial infection | 1653 | 196 (11.9) | |
| Heart failure | 1641 | 36 (2.2) | |
| Thrombosis | 1623 | 59 (3.6) | |
| COVID-19 treatment | |||
| ICU admission | 1650 | 314 (19.0) | |
| Intubation | 1649 | 183 (11.1) | |
| ECMO | 1641 | 37 (2.3) | |
| Antiviral drugs | |||
| 1657 | Favipiravir | 595 (35.9) | |
| 1645 | Ritonavir | 7 (0.4) | |
| 1648 | Remdesivir | 311 (18.9) | |
| Hydroxychloroquine | 1647 | 18 (1.1) | |
| Tocilizumab | 1643 | 118 (7.2) | |
| Systemic corticosteroid | 1663 | 680 (40.9) |
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease; CRP, C-reactive protein; CT, computed tomography; ECMO, extracorporeal membrane; GGO, ground glass opacity; ICU, intensive care unit; IQR, interquartile range; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; PCT, procalcitonin; WBC, white blood cell.
Figure 1Coronavirus disease (COVID-19) epidemic trend in Japan, from February 2020 to February 2021. The epidemic curve shows the three epidemic waves during 1 year in Japan. Red bar shows the first wave including 89 patients in this study; from April 1 to 28, 2020. Blue bar shows the second wave including 468 patients in this study; from July 1 to September 1, 2020. Green bar shows the third wave including 564 patients in this study; from November 18, 2020 to February 9, 2021. ■ Black bar shows the number of new patients during the period not included in the three epidemic waves. We created this figure using GraphPad Prism 9 (GraphPad Software, San Diego, California).